Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to Rhizopus arrhizus.

1-aminobenzotriazole APX001 APX001A Gwt1 MGX Rhizopus arrhizus antifungal antifungal agents fosmanogepix infection model infectious disease manogepix mucormycosis

Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
21 05 2020
Historique:
received: 23 01 2020
accepted: 17 03 2020
pubmed: 25 3 2020
medline: 22 6 2021
entrez: 25 3 2020
Statut: epublish

Résumé

Mucormycosis is a life-threatening infection with high mortality that occurs predominantly in immunocompromised patients. Manogepix (MGX) is a novel antifungal that targets Gwt1, a protein involved in an early step in the conserved glycosylphosphotidyl inositol (GPI) posttranslational modification pathway of surface proteins in eukaryotic cells. Inhibition of fungal inositol acylation by MGX results in pleiotropic effects, including inhibition of maturation of GPI-anchored proteins necessary for growth and virulence. MGX has been previously shown to have

Identifiants

pubmed: 32205345
pii: AAC.00178-20
doi: 10.1128/AAC.00178-20
pmc: PMC7269494
pii:
doi:

Substances chimiques

Antifungal Agents 0
Isoxazoles 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI063503
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201000038I
Pays : United States

Informations de copyright

Copyright © 2020 Gebremariam et al.

Références

Clin Infect Dis. 2002 Apr 1;34(7):909-17
pubmed: 11880955
Antimicrob Agents Chemother. 2020 Feb 21;64(3):
pubmed: 31818813
Clin Infect Dis. 2004 Aug 15;39(4):588-90
pubmed: 15356828
Antimicrob Agents Chemother. 2019 Jan 29;63(2):
pubmed: 30455236
J Clin Invest. 2014 Jan;124(1):237-50
pubmed: 24355926
Antimicrob Agents Chemother. 2018 Feb 23;62(3):
pubmed: 29311065
Antimicrob Agents Chemother. 2011 Oct;55(10):4652-8
pubmed: 21825291
J Antimicrob Chemother. 2017 Feb;72(2):462-466
pubmed: 27798213
Clin Infect Dis. 2000 Jun;30(6):851-6
pubmed: 10852735
Clin Infect Dis. 2003 Jul 15;37(2):221-9
pubmed: 12856215
Clin Infect Dis. 2012 Dec;55(11):1441-9
pubmed: 23042971
Antimicrob Agents Chemother. 2018 Jul 27;62(8):
pubmed: 29891599
Antimicrob Agents Chemother. 2013 Jul;57(7):3340-7
pubmed: 23650163
Antimicrob Agents Chemother. 2012 Jan;56(1):352-7
pubmed: 22083469
Antimicrob Agents Chemother. 2014;58(4):2450-3
pubmed: 24492363
Drug Metab Dispos. 2002 Oct;30(10):1059-62
pubmed: 12228180
Antimicrob Agents Chemother. 2018 Sep 24;62(10):
pubmed: 30012766
Antimicrob Agents Chemother. 2011 Oct;55(10):4543-51
pubmed: 21788462
Antimicrob Agents Chemother. 2018 Dec 21;63(1):
pubmed: 30373791
Mol Microbiol. 2002 Apr;44(1):61-72
pubmed: 11967069
Antimicrob Agents Chemother. 2019 Mar 27;63(4):
pubmed: 30670426
Clin Infect Dis. 2005 Sep 1;41(5):634-53
pubmed: 16080086
Lancet Infect Dis. 2019 Dec;19(12):e405-e421
pubmed: 31699664
Antimicrob Agents Chemother. 2013 Nov;57(11):5642-8
pubmed: 24002092
Antimicrob Agents Chemother. 2019 Jan 29;63(2):
pubmed: 30455238
J Antimicrob Chemother. 2019 May 1;74(5):1295-1299
pubmed: 30753499
Diagn Microbiol Infect Dis. 2011 Oct;71(2):167-70
pubmed: 21696907
Antimicrob Agents Chemother. 2018 Mar 27;62(4):
pubmed: 29378706
Lancet Infect Dis. 2016 Jul;16(7):828-837
pubmed: 26969258
Antimicrob Agents Chemother. 2018 Sep 24;62(10):
pubmed: 30061288

Auteurs

Teclegiorgis Gebremariam (T)

The Lundquist Institute for Biomedical Innovations at Harbor-University of California Los Angeles (UCLA) Medical Center, Torrance, California, USA.

Sondus Alkhazraji (S)

The Lundquist Institute for Biomedical Innovations at Harbor-University of California Los Angeles (UCLA) Medical Center, Torrance, California, USA.

Abdullah Alqarihi (A)

The Lundquist Institute for Biomedical Innovations at Harbor-University of California Los Angeles (UCLA) Medical Center, Torrance, California, USA.

Nathan P Wiederhold (NP)

University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.

Karen Joy Shaw (KJ)

Hearts Consulting Group, San Diego, California, USA kshaw@amplyx.com ibrahim@lundquist.org.

Thomas F Patterson (TF)

University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
South Texas Veterans Health Care System, San Antonio, Texas, USA.

Scott G Filler (SG)

The Lundquist Institute for Biomedical Innovations at Harbor-University of California Los Angeles (UCLA) Medical Center, Torrance, California, USA.
David Geffen School of Medicine at UCLA, Los Angeles, California, USA.

Ashraf S Ibrahim (AS)

The Lundquist Institute for Biomedical Innovations at Harbor-University of California Los Angeles (UCLA) Medical Center, Torrance, California, USA kshaw@amplyx.com ibrahim@lundquist.org.
David Geffen School of Medicine at UCLA, Los Angeles, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH